EAACI Congress 2024
BackFT 23 - Flash talks on Allergen Immunotherapy 3
Monday 03 Jun, 11:00 AM -
12:30 PM Valencia, Spain
Palma
Flash Talks
11:00
Safety and tolerability of ultra-rush induction protocols with Hymenoptera venoms using depot extracts
11:07
Differential effects of IgG4 vs IgE in birch allergy: blocking activity, receptor specificity and selective tropism of IgE-Bet v1 vs IgG4 immune complexes to B cells and monocytes
11:14
Safety and tolerability of in-season initiation of subcutaneous and sublingual allergen immunotherapy with SQ grass pollen products: a comprehensive review
11:21
Efficacy of virus-like particle (VLP)-based immunotherapy in a mouse model of HDM allergy
11:28
Poloxamer formulation for allergen immunotherapy reduces systemic allergic reactions in a mouse model
11:35
DRAGO Application: Implementing Adherence and to House Dust Mite Allergen Immunotherapy
11:42
ILIT.NU: Intralymphatic immunotherapy and placebo affected cSMS similarly in grass pollen allergic individuals in a large clinical trial
11:49
Sympout study: Evolution of clinical parameters in a pediatric population allergic to pollens or house dust mites treated with sublingual immunotherapy in liquid formulation standardized in TBU/ml
11:56
Sublingual immunotherapy for house dust mite allergy induces expansions of allergen-specific memory B cells expressing CD29 and downregulating IL4Rα
12:03
One-strength dose escalation using a birch pollen allergoid for subcutaneous immunotherapy is safe and well-tolerated in children, adolescents and adults
